Research Africa

September 5th, 2018 The HAVEN 3 study, led by a University of the Witwatersrand researcher, found that emicizumab prophylaxis (trade name: Hemlibra) administered subcutaneously once weekly or every two weeks led to a significantly lower bleeding rate. People with...
Page 4 of 9...23456...

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.